...
机译:Capecitabine Plus顺铂的随机期II试验与S-1加顺铂作为晚期胃癌的一线治疗:Capecitabine Plus顺铂确定与S-1加上顺铂随机化PII试验(XParts II)
Osaka Natl Hosp Dept Surg Osaka Japan;
Tsuboi Canc Ctr Hosp Dept Surg Koriyama Fukushima Japan;
Kanagawa Canc Ctr Dept Gastrointestinal Surg Yokohama Kanagawa Japan;
Kochi Med Sch Dept Human Hlth &
Med Sci Nankoku Kochi Japan;
Osaka Gen Med Ctr Dept Surg Osaka Japan;
Teikyo Univ Dept Surg Sch Med Tokyo Japan;
Aichi Hosp Dept Surg Aichi Canc Ctr Okazaki Aichi Japan;
Hiroshima Univ Dept Gastroenterol &
Transplant Surg Hiroshima Japan;
Gifu Univ Dept Surg Oncol Gifu Japan;
Yamaguchi Univ Ctr Oncol Ube Yamaguchi Japan;
Yokohama Municipal Citizens Hosp Div Gastroenterol Surg Yokohama Kanagawa Japan;
Hiroshima City Asa Hosp Dept Surg Hiroshima Japan;
Saga Ken Med Ctr Koseikan Dept Surg Gastroenterol Saga Japan;
Ebina Gen Hosp Dept Surg Ebina Kanagawa Japan;
Yokohama City Univ Dept Surg Yokohama Kanagawa Japan;
Obihiro Kosei Gen Hosp Dept Internal Med 3 Obihiro Hokkaido Japan;
Kanagawa Canc Ctr Dept Gastrointestinal Surg Yokohama Kanagawa Japan;
Kanagawa Canc Ctr Mol Pathol &
Genet Div Res Inst Yokohama Kanagawa Japan;
Fukushima Med Univ Adv Clin Res Ctr Fukushima Japan;
Japanese Fdn Canc Res Dept Gastroenterol Chemotherapy Canc Inst Hosp Tokyo Japan;
Epidemiol &
Clin Res Informat Network ECRIN Okazaki Aichi Japan;
Kyoto Univ Grad Sch Med Dept Biomed Stat &
Bioinformat Kyoto Japan;
Epidemiol &
Clin Res Informat Network ECRIN Okazaki Aichi Japan;
Advanced gastric cancer; First-line chemotherapy; Capecitabine plus cisplatin (XP); S-1 plus cisplatin (SP); Histological subtypes;
机译:Capecitabine Plus顺铂的随机期II试验与S-1加顺铂作为晚期胃癌的一线治疗:Capecitabine Plus顺铂确定与S-1加上顺铂随机化PII试验(XParts II)
机译:一项II期临床试验,以阐明卡培他滨加顺铂(XP)和S-1加顺铂(SP)作为晚期胃癌的一线治疗的有效性:XP确定性与SP随机PII试验(XParTS II)
机译:一项II期随机试验,以阐明卡培他滨加顺铂(XP)和S-1加顺铂(SP)作为晚期胃癌的一线治疗的有效性:XP确定性与SP随机PII试验(XParTS II)
机译:腹腔镜辅助胃切除术后,在术前S-1加顺铂术后成功处理了阶段IV胃癌的阶段胃癌。
机译:吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
机译:一项II期临床试验以阐明卡培他滨加顺铂(XP)和S-1加顺铂(SP)作为晚期胃癌的一线治疗的有效性:XP确定性与SP随机PII试验(XParTS II)
机译:一项II期临床试验,以阐明卡培他滨加顺铂(XP)和S-1加顺铂(SP)作为晚期胃癌的一线治疗的有效性:XP确定性与SP随机PII试验(XParTS II)